You are here
Distribution and geographic accessibility of prostate cancer clinical trials in the United States.
J Clin Oncol 32, 2014 (suppl 4; abstr 59)
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: An extremely small proportion of patients with cancer in the United States (US) enroll in clinical trials. While several barriers to trial accrual have been described, the geographic distribution and accessibility of clinical trial sites has not been comprehensively explored. Methods: ClinicalTrials.gov was queried to identify all active US clinical trials exploring first-line therapies for metastatic prostate cancer (PCa) on 9/16/2012. We evaluated the geographic distribution of trial sites and determined the relationship between the number of sites and the number of patients with advanced PCa per county and evaluated heterogeneity using Lorenz curves. We also estimated the minimum driving distance required to access a clinical trial site from each ZIP code in the continguous US; a distance >30 miles was defined as high travel burden consistent with prior studies. Results: We identified 958 sites associated with 42 PCa clinical trials (Table). The geographic distribution of clinical trial sites was very inhomogeneous with several states having only 1-2 trial sites. Among 3185 US counties, 2,669 (83.8%) had no clinical trials available for first-line treatment of metastatic PCa. Counties with larger populations of patients with advanced PCa had significantly higher numbers of clinical trial sites. For every 100 additional patients with advanced PCa per county, the number of available trial sites increased by 21.0% (95% CI: 16.5-25.7%). However, Lorenz curves indicated a high degree of inequality in trial accessibility (Gini index 0.71). Approximately 31% of the US population resided >30 miles from a PCa trial site. Conclusions: Clinical trials sites are poorly accessible, geographically, to a large subset of US PCa patients, a finding that likely contributes to dismal accrual. Innovative solutions are required to address geographic barriers to access.
|Median number sites per trial (range)||2 (1-301)|
|Median anticipated enrollment (range)||65 (20-1,200)|
Abstracts by Matt D. Galsky:
Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.Category: Genitourinary Cancer - Prostate Cancer
Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer.
Presentations by Matt D. Galsky:
Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).Session: General Poster Session A: Prostate Cancer (General Poster Session)
Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.Session: General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma (General Poster Session)
Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.Session: General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma (General Poster Session)